Los Angeles Capital Management LLC Decreases Stake in Humana Inc. (NYSE:HUM)

Los Angeles Capital Management LLC cut its holdings in shares of Humana Inc. (NYSE:HUM) by 31.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,079 shares of the insurance provider’s stock after selling 10,697 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Humana were worth $10,566,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently modified their holdings of the company. Morgan Stanley grew its holdings in Humana by 6.2% during the 3rd quarter. Morgan Stanley now owns 2,040,896 shares of the insurance provider’s stock valued at $992,938,000 after buying an additional 119,760 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in Humana by 35.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock worth $741,409,000 after purchasing an additional 402,559 shares in the last quarter. Northern Trust Corp boosted its holdings in Humana by 5.1% in the 3rd quarter. Northern Trust Corp now owns 1,327,489 shares of the insurance provider’s stock valued at $645,850,000 after purchasing an additional 64,245 shares during the period. Invesco Ltd. raised its position in shares of Humana by 1.4% in the third quarter. Invesco Ltd. now owns 965,488 shares of the insurance provider’s stock worth $469,729,000 after buying an additional 13,670 shares in the last quarter. Finally, AQR Capital Management LLC boosted its stake in Humana by 39.3% during the third quarter. AQR Capital Management LLC now owns 681,868 shares of the insurance provider’s stock valued at $331,743,000 after buying an additional 192,546 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Down 0.1 %

Shares of NYSE HUM opened at $320.54 on Friday. The firm’s fifty day moving average is $324.12 and its 200 day moving average is $388.34. Humana Inc. has a 52 week low of $298.61 and a 52 week high of $541.21. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.77. The company has a market cap of $38.63 billion, a price-to-earnings ratio of 19.96, a PEG ratio of 1.86 and a beta of 0.49.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. The firm had revenue of $29.61 billion for the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $9.38 earnings per share. On average, equities research analysts expect that Humana Inc. will post 16.18 earnings per share for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.10%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s payout ratio is 22.04%.

Wall Street Analysts Forecast Growth

HUM has been the topic of a number of recent analyst reports. Cantor Fitzgerald lowered their target price on shares of Humana from $391.00 to $360.00 and set a “neutral” rating on the stock in a research note on Thursday, April 25th. UBS Group dropped their price objective on shares of Humana from $334.00 to $326.00 and set a “neutral” rating for the company in a report on Thursday, April 25th. Argus lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, March 13th. TheStreet downgraded Humana from a “b” rating to a “c+” rating in a research report on Monday, January 8th. Finally, Oppenheimer cut their price objective on Humana from $415.00 to $370.00 and set an “outperform” rating for the company in a report on Thursday, April 25th. Eleven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $424.50.

Insiders Place Their Bets

In other Humana news, Director Jorge S. Mesquita bought 545 shares of Humana stock in a transaction dated Tuesday, February 20th. The shares were purchased at an average cost of $367.09 per share, with a total value of $200,064.05. Following the completion of the purchase, the director now owns 2,578 shares of the company’s stock, valued at $946,358.02. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.32% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.